In the Liraglutide Effect and Action in Diabetes Trial (LEAD-3), treatment with the GLP-1 RA liraglutide significantly reduced body fat, but there was no significant reduction in lean body mass [42]. This evidence concerns the gene GCG and diabetes mellitus.